MedTrace Logo

BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

NCT04880889 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2022-07-08

No results posted yet for this study

Summary

Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.

Research product: BL3000. Reference product: Pantogar® List of Study Center: MAIN INVESTIGATOR STUDY CENTER FONE Medcin Skin Institute Sérgio Schalka 11 36835357

Conditions

  • Telogen Effluvium

Interventions

DRUG

BL 3000

capsule 500 mg

DRUG

Reference Pantogar

capsule

DRUG

BL3000 Placebo

capsule 500 mg

DRUG

Pantogar - Placebo

capsule

Sponsors & Collaborators

  • Biolab Sanus Farmaceutica

    lead INDUSTRY

Principal Investigators

  • Sérgio Schalka · Medcin Instituto da Pele

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-07-30
Completion
2023-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04880889 on ClinicalTrials.gov